Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 102

Related Citations for PubMed (Select 24853176)

1.

MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.

Nagy E, Gajjar KB, Patel II, Taylor S, Martin-Hirsch PL, Stringfellow HF, Martin FL, Phillips DH.

Br J Cancer. 2014 Jun 10;110(12):2874-80. doi: 10.1038/bjc.2014.263. Epub 2014 May 22.

PMID:
24853176
2.

Molecular genetic characterization of tamoxifen-associated endometrial cancer.

Prasad M, Wang H, Douglas W, Barakat RR, Ellenson LH.

Gynecol Oncol. 2005 Jan;96(1):25-31.

PMID:
15589576
3.

Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.

Yasue A, Hasegawa K, Udagawa Y.

Hum Cell. 2011 Jun;24(2):65-73. doi: 10.1007/s13577-010-0005-9. Epub 2011 Jan 22.

PMID:
21547354
4.

MGMT promoter hypermethylation is a frequent, early, and consistent event in astrocytoma progression, and not correlated with TP53 mutation.

Groenendijk FH, Taal W, Dubbink HJ, Haarloo CR, Kouwenhoven MC, van den Bent MJ, Kros JM, Dinjens WN.

J Neurooncol. 2011 Feb;101(3):405-17. doi: 10.1007/s11060-010-0274-x. Epub 2010 Jul 1.

5.

MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.

de Vogel S, Weijenberg MP, Herman JG, Wouters KA, de Goeij AF, van den Brandt PA, de Bruïne AP, van Engeland M.

Ann Oncol. 2009 Jul;20(7):1216-22. doi: 10.1093/annonc/mdn782. Epub 2009 Jan 22.

6.

Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.

Suehiro Y, Wong CW, Chirieac LR, Kondo Y, Shen L, Webb CR, Chan YW, Chan AS, Chan TL, Wu TT, Rashid A, Hamanaka Y, Hinoda Y, Shannon RL, Wang X, Morris J, Issa JP, Yuen ST, Leung SY, Hamilton SR.

Clin Cancer Res. 2008 May 1;14(9):2560-9. doi: 10.1158/1078-0432.CCR-07-1802.

7.

Association of O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation with p53 mutation occurrence in non-small cell lung cancer with different histology, gender, and smoking status.

Wu JY, Wang J, Lai JC, Cheng YW, Yeh KT, Wu TC, Chen CY, Lee H.

Ann Surg Oncol. 2008 Nov;15(11):3272-7. doi: 10.1245/s10434-008-0078-9. Epub 2008 Aug 20.

PMID:
18712569
8.

Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen.

Turbiner J, Moreno-Bueno G, Dahiya S, Sánchez-Estevez C, Hardisson D, Prat J, Oliva E, Palacios J.

Mod Pathol. 2008 Aug;21(8):925-36. doi: 10.1038/modpathol.2008.49. Epub 2008 May 23.

9.

Monitoring of endometrial K-ras mutation in tamoxifen-treated patients with breast cancer.

Tsujioka H, Hachisuga T, Fukuoka M, Ueda T, Miyahara D, Horiuchi S, Shirota K, Yoshizato T, Emoto M, Miyamoto S, Kawarabayashi T.

Int J Gynecol Cancer. 2009 Aug;19(6):1052-6. doi: 10.1111/IGC.0b013e3181a8b0aa.

PMID:
19820367
10.

MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.

Mellai M, Monzeglio O, Piazzi A, Caldera V, Annovazzi L, Cassoni P, Valente G, Cordera S, Mocellini C, Schiffer D.

J Neurooncol. 2012 May;107(3):617-31. doi: 10.1007/s11060-011-0787-y.

PMID:
22287028
11.

MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.

Shima K, Morikawa T, Baba Y, Nosho K, Suzuki M, Yamauchi M, Hayashi M, Giovannucci E, Fuchs CS, Ogino S.

Cancer Causes Control. 2011 Feb;22(2):301-9. doi: 10.1007/s10552-010-9698-z. Epub 2010 Dec 8.

12.

Methylation pattern of the O6-methylguanine-DNA methyltransferase gene in colon during progressive colorectal tumorigenesis.

Nagasaka T, Goel A, Notohara K, Takahata T, Sasamoto H, Uchida T, Nishida N, Tanaka N, Boland CR, Matsubara N.

Int J Cancer. 2008 Jun 1;122(11):2429-36. doi: 10.1002/ijc.23398.

13.

MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy.

Bobustuc GC, Smith JS, Maddipatla S, Jeudy S, Limaye A, Isley B, Caparas ML, Constantino SM, Shah N, Baker CH, Srivenugopal KS, Baidas S, Konduri SD.

Mol Med. 2012 Sep 7;18:913-29. doi: 10.2119/molmed.2012.00010. Erratum in: Mol Med. 2012;18: doi/10.2119/molmed.2012.00006.erratum.

14.

MGMT methylation is associated primarily with the germline C>T SNP (rs16906252) in colorectal cancer and normal colonic mucosa.

Hawkins NJ, Lee JH, Wong JJ, Kwok CT, Ward RL, Hitchins MP.

Mod Pathol. 2009 Dec;22(12):1588-99. doi: 10.1038/modpathol.2009.130. Epub 2009 Sep 4.

15.

Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis.

Esteller M, Toyota M, Sanchez-Cespedes M, Capella G, Peinado MA, Watkins DN, Issa JP, Sidransky D, Baylin SB, Herman JG.

Cancer Res. 2000 May 1;60(9):2368-71.

16.

Promoter methylation status of MGMT, hMSH2, and hMLH1 and its relationship to corresponding protein expression and TP53 mutations in human esophageal squamous cell carcinoma.

Su Y, Yin L, Liu R, Sheng J, Yang M, Wang Y, Pan E, Guo W, Pu Y, Zhang J, Liang G.

Med Oncol. 2014 Feb;31(2):784. doi: 10.1007/s12032-013-0784-4. Epub 2013 Dec 24.

PMID:
24366688
17.
18.

Association between MGMT promoter hypermethylation and p53 mutation in glioblastoma.

Shamsara J, Sharif S, Afsharnezhad S, Lotfi M, Raziee HR, Ghaffarzadegan K, Moradi A, Rahighi S, Behravan J.

Cancer Invest. 2009 Oct;27(8):825-9. doi: 10.1080/07357900902783211.

PMID:
19544111
19.

Methylation of O6-methylguanine-DNA methyltransferase (MGMT) promoter gene in triple-negative breast cancer patients.

Fumagalli C, Pruneri G, Possanzini P, Manzotti M, Barile M, Feroce I, Colleoni M, Bonanni B, Maisonneuve P, Radice P, Viale G, Barberis M.

Breast Cancer Res Treat. 2012 Jul;134(1):131-7. doi: 10.1007/s10549-011-1945-9. Epub 2012 Jan 8.

PMID:
22228432
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk